. 2020 Apr 21;64(5):e02375-19. doi: 10.1128/AAC.02375-19

TABLE 4.

Activities of KBP-7072 and comparators against 304 meropenem-resistant Acinetobacter baumannii isolates

Antimicrobial agent (no. of isolates tested)	MIC range (mg/liter)	MIC_50/90 (mg/liter)	CLSI^a			EUCAST^a
Antimicrobial agent (no. of isolates tested)	MIC range (mg/liter)	MIC_50/90 (mg/liter)	% S	% I	% R	% S	% I	% R
KBP-7072 (304)	0.03 to 4	0.5/1	98.7^b
Tigecycline (304)	0.12 to 16	2/4	65.5^c	30.9	3.6
Doxycycline (274)	≤0.06 to >8	8/>8	49.3	2.9	47.8
Minocycline (275)	≤0.03 to >8	2/>8	57.8	10.9	31.3
Tetracycline (278)	1 to >8	>8/>8	8.6	7.2	84.2
Ceftazidime (304)	1 to >16	>16/>16	5.3	6.2	88.5
Colistin (301)	≤0.5 to >8	≤0.5/2	90.7		9.3	90.7		9.3
Gentamicin (304)	≤2 to >8	>8/>8	16.8	7.2	76.0	16.8		83.2
Levofloxacin (304)	0.12 to >4	>4/>4	1.6	3.3	95.1	1.6	0.0	98.4
Meropenem (304)	8 to >8	>8/>8	0.0	0.0	100.0	0.0	2.6	97.4
Piperacillin-tazobactam (304)	64 to >64	>64/>64	0.0	1.3	98.7

Criteria according to CLSI (2019) and EUCAST (2019) guidelines (22, 24).

Percent inhibited at ≤2 mg/liter for comparison purposes only. The highest MIC was 4 mg/liter.

Tigecycline FDA breakpoint criteria for Enterobacteriaceae applied to A. baumannii isolates for comparison purposes only (25).